

Supplementary table. Diabetes urinary biomarkers: attributed and unattributed proteins. <sup>a</sup>Accession number in National Center for Biotechnology Information databases.  
DM= Diabetic patients; DN= Diabetic nephropathy; DM-NP= Diabetic patients with macro- or microalbuminuria.

<i>m/z</i>	PROTEIN NAME	ACCESSION NUMBER <sup>a</sup>	BIOLOGICAL PROCESS	DISEASE	REGULATION	METHOD/S	REFERENCE
482	Alpha-2-HS-glycoprotein [321-339]	P02765	Mineral balance	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
544	Beta-2-microglobulin [59-81]	P61769	Defense response	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
605	CD99 antigen [97-129]	P14209	Cell adhesion	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
608	Serum albumin [25-45]	P02768	Transport	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
636	Serum albumin [25-46]	P02768	Transport	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
661	Serum albumin [25-47]	P02768	Transport	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
671	Collagen alpha-1 (III) chain [796-809]	P02461	Structural Component	Type 2 DM	down-regulated	CZE followed by Ion trap	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
720	Collagen alpha-1 (III) chain [642-657]	P02461	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
733	Collagen alpha-1 (I) chain [1011-1041]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
735	Uromodulin [594-606]	P07911	Defense response	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
797	Alpha-1-antitrypsin [398-418]	P01009	Defense response	Type 2 DM	up-regulated	CZE followed by Ion trap	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
803	oxidated Alpha-1-antitrypsin [398-418]	P01009	Defense response	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
803	Collagen alpha-1 (I) chain [273-299]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
805	Membrane-associated progesterone receptor component 1 [53-67]	O00264	Metabolism	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
809	Collagen alpha-1 (I) chain [273-299]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
811	Collagen alpha-1 (I) chain [819-846]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
817	Collagen alpha-1 (I) chain [588-624]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
840	Alpha-1-antitrypsin [397-418]	P01009	Defense response	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>

897	Collagen alpha-1 (I) chain [612-641]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
910	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
915	Collagen alpha-1 (III) chain [610-639]	P02461	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
937	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
969	Collagen alpha-2 (I) chain [844-865]	P08123	Structural Component	Type 2 DM	down-regulated	CZE followed by Ion trap	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
973	Alpha-1-antitrypsin [378-394]	P01009	Defense response	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
981	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
986	Transthyretin [130-147]	P02766	Transport	Type 2 DM	up-regulated	CZE followed by Ion trap	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
995	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,008	Collagen alpha-1 (III) chain [176 -198]	P02461	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,009	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,011	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,029	Collagen alpha-1 (I) chain [433-455]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,032	Collagen alpha-2 (I) chain [831-865]	P08123	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,032	Collagen alpha-1 (I) chain [819-854]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,037	Collagen alpha-1 (I) chain[ 819-854]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,048	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,060	Collagen alpha-1 (III) chain [886-909]	P02461	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,078	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1290.</i>
1,094	Collagen alpha-1 (I) chain [432-455]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,107	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>

1,109	Alpha-1-antitrypsin [124-143]	P01009	Defense response	Type 2 DM	up-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,109	Collagen alpha-1 (I) chain [769-794]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,128	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,135	Collagen $\alpha$ -2 (IV) chain	J04217.1	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,142	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,142	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,160	Uromodulin	P07911	Defense response	Type 2 DM	up-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,210	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-130</i>
1,219	Collagen $\alpha$ -5 (IV) chain precursor	P29400	Structural Component	Type 2 DM-NP and NP	up-regulated	MALDI/TOF/TOF	<i>Lapolla A. et al. J Mass Spectrom. 2009;44: 419-427</i>
1,225	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,233	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,237	Collagen alpha-1 (I) chain [766-794]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Ion trap	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,245	Collagen alpha-1 (I) chain [818-846]	P02452	Structural Component	Type 2 DM	down-regulated	CZE followed by Orbitrap (ETD)	<i>Alkhalaf A et al. PLoS One. 2010;5(10):e13421</i>
1,325	Collagen $\alpha$ -1 (III) chain	P02461	Structural Component	Type 2 DM-NP	up-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,327	Collagen type 3 $\alpha$ 1	Unknown	Structural Component	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,327	Collagen alpha-1 (III) chain	P02461	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,332	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,333	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>

1,354	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283–1286</i>
1,358	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,368	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,397	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283–1290.</i>
1,404	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,408	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,425	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,439	Collagen alpha-1 (III) chain	P02461	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,443	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,452	Collagen alpha-1 (III) chain	P02461	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,463	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,466	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,484	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,485	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,486	Collagen $\alpha$ -1 (I) chain [829 to 835]	P02452	Structural Component	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283–1286</i>
1,487	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283–1286</i>
1,524	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,527	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283–1286</i>

1,530	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,540	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,546	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,550	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,562	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,567	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,578	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,595	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,597	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,610	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,652	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,680	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,680	Uromodulin	P07911	Defense response	Type 2 DM	up-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,699	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,717	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,717	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,726	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,733	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,789	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>

1,818	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,819	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,844	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,847	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
1,851	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,864	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,866	Collagen $\alpha$ -1 (I) chain [279 to 299]	P02452	Structural Component	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,867	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,873	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,886	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,893	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,912	uromodulin precursor	P07911	Defense response	Type 2 DM-NP and NP	down-regulated	MALDI/TOF/TOF	<i>Lapolla A. et al. J Mass Spectrom. 2009;44: 419-426</i>
1,937	Collagen $\alpha$ -2 (I) chain [844 to 865]	P08123	Structural Component	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
1,955	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
1,971	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,020	Collagen alpha-1 (III) chain	P02461	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
2,032	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,039	Uromodulin [589 to 607]	P07911	Defense response	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>

2,047	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	Rossing K. et al. <i>J Am Soc Nephrol.</i> 2008;19:1283–1286
2,049	Collagen $\alpha$ -1 (I) chain precursor	P02452	Structural Component	Type 2 DM-NP and NP	up-regulated	MALDI/TOF/TOF	Lapolla A. et al. <i>J Mass Spectrom.</i> 2009;44: 419-425
2,061	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,063	Collagen alpha-1 (III) chain	P02461	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	Maahs DM. et al. <i>PLoS One.</i> 2010;5(9): e13051.
2,092	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,119	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,186	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,192	Collagen $\alpha$ -1 (I) chain	P02452	Structural Component	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	Rossing K. et al. <i>J Am Soc Nephrol.</i> 2008;19:1283–1286
2,192	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	Maahs DM. et al. <i>PLoS One.</i> 2010;5(9): e13051.
2,228	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,230	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,257	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,339	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	Rossing K. et al. <i>J Am Soc Nephrol.</i> 2008;19:1283–1286
2,339	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	Maahs DM. et al. <i>PLoS One.</i> 2010;5(9): e13051.
2,377	Collagen $\alpha$ -1 (I) chain [227 to 250]	P02452	Structural Component	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	Rossing K. et al. <i>J Am Soc Nephrol.</i> 2008;19:1283–1286
2,406	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,424	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95
2,427	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	Mischak H. et al. <i>Clin Sci.</i> 2004;107:485-95

2,430	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
2,465	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,487	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
2,494	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,522	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,541	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,551	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
2,574	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
2,587	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,644	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,670	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,687	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
2,698	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,711	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,734	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
2,749	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
2,751	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
2,791	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>



2,796	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,803	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
2,937	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,959	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
2,995	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,081	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
3,092	Collagen alpha-1(I) chain	P02452	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
3,109	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,224	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,246	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,293	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,296	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,334	Unattributed	Unattributed	Unknown	Type 2 DM-NP	up-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1290.</i>
3,364	Unattributed	Unattributed	Unknown	Type 2 DM-NP	up-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1290.</i>
3,479	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
3,617	Collagen alpha-2(I) chain	P08123	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
3,658	Unattributed	Unattributed	Unknown	Type 2 DM-NP	down-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
3,670	Unattributed	Unattributed	Unknown	Type 2 DM-NP	up-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>

3,802	Collagen alpha-2(I) chain	P08123	Structural Component	Type 2 DM	down-regulated with respect to Type 1 DM	CZE-MS	<i>Maahs DM. et al. PLoS One. 2010;5(9): e13051.</i>
4,714	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
4,864	Unattributed	Unattributed	Unknown	Type 2 DM	down-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
4,962	Unattributed	Unattributed	Unknown	Type 2 DM	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-95</i>
5,574	Unattributed	Unattributed	Unknown	Type 2 DM-NP	up-regulated	CZE coupled with ESI mass spectrometry	<i>Rossing K. et al. J Am Soc Nephrol. 2008;19:1283-1286</i>
9,181	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-136</i>
10,046	Unattributed	Unattributed	Unknown	Type 2 DM with renal disease	up-regulated	CZE coupled with ESI mass spectrometry	<i>Mischak H. et al. Clin Sci. 2004;107:485-135</i>
11,773	Ig Kappa Chain C region	P01834	Defense response	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232-241.</i>
11,774	$\beta_2$ -microglobulin	P61769	Defense response	Type 2 DM-NP with Proteinuria	up-regulated	anion exchange, reversed-phase fractionation, gel electrophoresis and SELDI-TOF MS	<i>Dihazi H. et al. Clin Chem. 2007;53(9):1636-45</i>
13,234	Calgranulin B	P06702	Defense response	Type 2 DM-NP	up-regulated	Using DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
14,766	UbA52	P62987	Metabolism	Type 2 DM-NP with Proteinuria	up-regulated	anion exchange, reversed-phase fractionation, gel electrophoresis and SELDI-TOF MS	<i>Dihazi H. et al. Clin Chem. 2007;53(9):1636-45</i>
15,877	Transthyretin precursor	P02766	Metabolism	Type 2 DM-NP	down-regulated	Using DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
15,991	Transthyretin	P02766	Transport	Type 2 DM	down-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
15,991	Transthyretin precursor	P02766	Transport	Type 2 DM-NP	downregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232-241.</i>
21,243	Prostaglandin-H2D-isomerase precursor	P41222	Metabolism	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232-241.</i>

22,995	Plasma retinol-binding protein	P02753	Signal trasduction	Type 2 DM-NP	down-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
23,371	Retinol binding protein 4	P02753	Transport	Type 2 DM	up-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
23,371	Plasma retinol-binding protei precursor	P02753	Signal trasduction	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
23,725	$\alpha$ 1-acid glycoprotein precursor	P02763	Transport	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
30,759	Apolipoprotein A-I	P02647	Metabolism	Type 2 DM-NP	down-regulated	Using DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-39</i>
34,079	Zinc- $\alpha$ 2-glycoprotein	P25311	Metabolism	Type 2 DM	up-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
34,079	Zinc- $\alpha$ 2-glycoprotein precursor	P25311	Metabolism	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
34,223	Zinc- $\alpha$ 2-glycoprotein	P25311	Defense response	Type 2 DM-NP	up-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
39,300	$\alpha$ 2-HS-glycoprotein	P02765	Metabolism	Type 2 DM-NP	up-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
39,886	$\alpha$ 1-microglobulin/bikunin precursor (AMBP)	P02760	Defense response	Type 2 DM	down-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
39,886	$\alpha$ 1-microglobulin/bikunin precursor (AMBP)	P02760	Defense response	Type 2 DM-NP	downregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
45,860	Haptoglobin precursor	P00738	Metabolism	Type 2 DM	down-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
45,861	Haptoglobin precursor	P00738	Metabolism	Type 2 DM-NP	downregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
46,707	$\alpha$ 1-antitrypsin	P01009	Defense response	Type 2 DM-NP	up-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>

51,643	$\alpha_1$ -microglobulin/bikunin precursor	P02790	Transport	Type 2 DM-NP	down-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
51,643	Hemopexin	P02790	Defense response	Type 2 DM-NP	up-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
52,964	Vitamin D-binding protein	P02774	Transport	Type 2 DM-NP	up-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
54,239	$\alpha_{1B}$ -Glycoprotein	P04217	Function not assigned	Type 2 DM-NP	up-regulated	DIGE followed LC/MS/MS peptide analysis	<i>Rao VP et al. Diabetes care. 2007;30:629-37</i>
71,317	Albumin	P02768	Transport	Type 2 DM	up-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
71,317	Serum albumin precursor	P02768	Transport	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
72,451	Uromodulin precursor	P07911	Defense response	Type 2 DM-NP	downregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
72,984	Kininogen precursor	P01042	Defense response	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>
97,853	Epithelial-cadherin	P12830	Cell adhesion	Type 2 DM	up-regulated	Two-Dimensional Liquid Chromatography followed by MALDI	<i>Riaz S. et al. Diabetes Technol Ther. 2010;12(12):979-88</i>
97,853	Epithelial-cadherin	P12830	Cell adhesion	Type 2 DM-NP	upregulated	DIGE followed MALDI-TOF-MS	<i>Jiang H. et al. Diabetes Metab Res Rev 2009; 25: 232–241.</i>